Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

1. Specific recommendations for prevention strategies often depend on the ischemic
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Executive summary 2020 will go down in history as the year when the global community was
awakened to the fragility of human health and the interdependence of the ecosystem …

Diabetes is one of the fastest growing diseases worldwide, projected to affect 693 million
adults by 2045. Devastating macrovascular complications (cardiovascular disease) and …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Although there has been substantial improvement in atherosclerotic cardiovascular disease
(ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and …

Background Patients with diabetes are at higher risk for death and cardiovascular outcomes
than the general population. We investigated whether the excess risk of death and …

One in 4 Americans> 40 years of age takes a statin to reduce the risk of myocardial
infarction, ischemic stroke, and other complications of atherosclerotic disease. The most …